Pilot experience with clopidogrel in the treatment of an .ST-elevation acute myocardial infarction


Aim. To examine efficacy of clopidogrel before thrombolytic therapy (TLT) in patients with acute myocardial infarction (AMI).
Material and methods. A total of 72 patients (48 males and 24 females) admitted to hospital within 6 hours since the onset of acute myocardial infarction (AMI) were divided into three groups. Group 1 and 2 patients (n = 38 and 20, respectively) were given a prehospital stress dose of aspirin (250- 500 mg), group 3 patients (n = 14) received this dose at admission. TLT with streptokinase or actilise (1500000 IU and 100 mg, respectively) was given to all the patients. Before TLT group 2 received a stress dose of clopidogrel (300 mg), after TLT - 75 mg/day. 12-Lead ECG, CFK activity and troponine content examinations were made. The patients were observed for 30 days. The recovery of coronary circulation (CC) was evaluated by dynamics of a total lowering of the elevated ST segment. Results. CC completely recovered 60 min after TLT in 16, 10 and 7% patients of groups 1, 2 and 3, respectively. CC recovered partially in 24, 55 and 7% patients, respectively. In 90 min after TLT partial recovery of CC was observed in 21, 31 and 43%, respectively; in 180 min the effect was absent in 19, 15 and 38%, respectively. 30-Day lethality was 11.1% and was high in group 3. No lethal outcomes were seen in group 2.
Conclusion. It is possible to achieve better myocardial reperfusion after TLT and improve 30-day outcomes in MI patients given combined antithrombocytic therapy.


  1. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without бТ-segment elevation. N. Engl. J. Med. 2001; 345: 494-502.
  2. Mehta S., Yusuf S., Peters R. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
  3. Steinhubl S. R., Berger P. В., Mann J. T. Ill et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. J. A. M. A. 2002; 288: 2411-2420.
  4. Schroder R., Wegscheider K., Schroder K. et al. For the INJECT trial group. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. J. Am. Coll. Cardiol. 1995; 26: 1657-1664.
  5. Zeymer U., Schroder R., Tebbe U. et al. Non-invasive detection of early infarct vessel patency by resolution of .ST-segment elevation in patients with thrombolysis for acute myocardial infarction. Results of the angiographic substudy of" the Hirudin for improvement of Thrombolysis (HIT)-4 trial. Eur. Heart J. 2001; 22: 769-775.
  6. Marrow D. A., Antman E. M., Charlesworth A. et al. TIMI risk score for .ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation. An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102: 2031.
  7. Simoons M. L., Krzeminska-Pacula M., Alonso A. et al. Improved reperfusion and clinical outcome with enoxaparine as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur. Heart J. 2002; 23: 1282- 1290.
  8. Savcic M., Hauert J., Bachmann A. et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin. Thromb. Hemost. 1999; 25 (suppl. 2): 15-19.
  9. Kovac J. D., Gershliclc A. H. Clinical perspective. How should we detect and manage failed thrombolysis? Eur. Heart J. 2001; 22: 450-457.
  10. Yusuf S., Mehta S. R., Zhao F. et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107: 966-972.



Abstract - 96


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2020 Shalaev S.V., Vorobyeva N.M., Serescheva A.K., Petrik E.S., Akinina S.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies